BiotechTube

Tenapanor

ApprovedCompleted
0 watching 0 views this week🔥 Hot
80
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

IBS

Conditions

IBS, IBS - Irritable Bowel Syndrome

Trial Timeline

Feb 6, 2024 → Dec 17, 2025

NCT ID
NCT05995899

About Tenapanor

Tenapanor is a approved stage product being developed by Ardelyx for IBS. The current trial status is completed. This product is registered under clinical trial identifier NCT05995899. Target conditions include IBS, IBS - Irritable Bowel Syndrome.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (6)

NCT IDPhaseStatus
NCT06810167Phase 3Recruiting
NCT05995899ApprovedCompleted
NCT06203444Phase 1Completed
NCT05905926Phase 3Recruiting
NCT04549597ApprovedCompleted
NCT02727751Phase 3Completed

Competing Products

12 competing products in IBS

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
52
linaclotide + PlaceboAstellas PharmaPhase 3
77
ONO-2952 + Placebo comparatorOno PharmaceuticalPhase 2
52
ONO-2952 + ONO-2952 Matching PlaceboOno PharmaceuticalPhase 2
52
Placebo + LinaclotideAstraZenecaPhase 3
77
TegaserodNovartisApproved
85
SMS995 + PlaceboNovartisPhase 1
33
DNK333 + PlaceboNovartisPhase 2
52
TenapanorArdelyxPhase 3
72
Tenapanor 50 MG + Tenapanor 25 mg bid + PlaceboArdelyxPhase 3
72
Tenapanor + PlaceboArdelyxPhase 2
47
MD-7246 + PlaceboIronwood PharmaceuticalsPhase 2
44

Other Products from Ardelyx

Tenapanor + Sevelamer CarbonateApproved
80
TenapanorApproved
80
TenapanorPhase 3
72
TenapanorPhase 3
72
Tenapanor 5 mg BID + Tenapanor 25 mg BID + Tenapanor 50 mg BID + PlaceboPhase 3
72